Objective: To determine the significance of the presence of foamy histiocytes (FH) in postmenopausal cervicovaginal smears for the detection of endometrial carcinomas (EC). Study Design: Endometrial sampling was performed over 6 months in 53 of 102 cases that presented with postmenopausal FH, benign endometrial cells (BEC), FH with BEC (FH + BEC), and atypical endometrial cells (AEC), resulting in a total of 41,150 cervicovaginal smears. The control group consisted of 58 cases with a cytologic diagnosis of a normal smear (NS). Results: There were 0 (0%), 1 (4.54%), 2 (13.33%), 2 (33.33%), and 5 (50.00%) cases of EC diagnosed on histopathologic evaluation in patients with NS (n = 58), BEC (n = 22), FH (n = 15), FH + BEC (n = 6), and AEC (n = 10), respectively. The sensitivities and specificities of the cytologic diagnoses of FH, FH + BEC, and AEC for the detection of EC were 81.7 and 100%, 93.6 and 100%, and 92.1 and 100%, respectively. Conclusion: The cytologic diagnoses of FH and FH + BEC had reasonably high sensitivities and specificities for the diagnosis of EC by cervicovaginal smear. Additional studies are needed.

1.
Ellenson LH, Ronnett BM, Kurman RJ: Precursor lesions of endometrial carcinoma; in Ellenson LH, Ronnett BM, Kurman RJ (eds): Blaustein's Pathology of the Female Genital Tract, ed 6. New York, Springer, 2011, pp 359-391.
2.
Nassar A, Fleisher SR, Nasuti JF: Value of histiocyte detection in Pap smears for predicting endometrial pathology: an institutional experience. Acta Cytol 2003;47:762-767.
3.
Wen P, Abramovich CM, Wang N, Knop N, Mansbacher S, et al: Significance of histiocytes on otherwise-normal cervical smears from postmenopausal women: a retrospective study of 108 cases. Acta Cytol 2003;47:135-140.
4.
Ivazzo C, Kalmantis K, Ntziora F, Balakitsas N, Paschalinopoulos D: Detection of large histiocytes in Pap smears: role in the prediction of endometrial pathology? Bratisl Lek Listy 2008;109:497-498.
5.
Tambouret R, Bell DA, Centeno BA: Significance of histiocytes in cervical smear from postmenopausal women. Diagn Cytopathol 2001;24:271-275.
6.
Nguyen TN, Bourdeu JL, Ferenczy A, Franco EL: Clinical significance of histiocytes in the detection of endometrial adenocarcinoma and hyperplasia. Diagn Cytopathol 1998;19:89-93.
7.
Fadare O, Ghofrani M, Chacho MS, Vinita P: The significance of benign endometrial cells in cervicovaginal smears. Adv Anat Pathol 2005;12:274-287.
8.
Moriarty AT, Cibas ES: Endometrial cells: the how and when of reporting; in Solomon D, Nayar R (eds): The Bethesda System for Reporting Cervical Cytology, ed 2. New York, Springer, 2004, pp 57-66.
9.
Covell JL, Wilbur DC, Guidos B, Lee KR, Chhieng DC, Mody DR: Epithelial abnormalities: glandular; in Solomon D, Nayar R (eds): The Bethesda System for Reporting Cervical Cytology, ed 2. New York, Springer, 2004, pp 123-156.
10.
Brogi E, Tambouret R, Bell DA: Classification of benign endometrial glandular cells in cervical smears from postmenopausal women. Cancer Cytopathol 2002;96:60-66.
11.
Saad RE, Takei H, Liu YL, Silverman JE, Lipscomb JT, Ruitz B: Clinical significance of a cytologic diagnosis of atypical glandular cells, favor endometrial origin, in Pap smears. Acta Cytol 2006;50:48-54.
12.
Zhao C, Austin RM, Pan J, Barr N, Martin SE, Raza A, Cobb C: Clinical significance of atypical glandular cells in conventional Pap smears in a large, high-risk US west coast minority population. Acta Cytol 2009;53:153-159.
13.
Zhou J, Tomashefski JF Jr, Sawady J, Ferrer H, Khiyami A: The diagnostic value of the ThinPrep Pap test in endometrial carcinoma: a prospective study with histological follow-up. Diagn Pathol 2013;41:408-412.
14.
Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346-355.
15.
Zarcone R, Cardone G, Voto RI, Longo M, Cardone A: The role of histiocytes in the cytodiagnosis of endometrial adenocarcinoma. Minerva Ginecol 1992;44:83-86.
16.
Schroeter L, Louw M, Michelow P, Wright C: Application of cytomorphologic features and immunohistochemistry to cervicovaginal smears: a scoring system to distinguish between endometrial and endocervical adenocarcinoma. Acta Cytol 2009;6:630-636.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.